menu
    • menu
    [{"orgOrder":0,"company":"Apeiron Biologics","sponsor":"Sensei Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Series B Financing","leadProduct":"Pembrolizumab","moa":"||Aspartyl-beta-hydroxylase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Apeiron Biologics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Injection","sponsorNew":"Apeiron Biologics \/ Apeiron Biologics","highestDevelopmentStatusID":"7","companyTruncated":"Apeiron Biologics \/ Apeiron Biologics"},{"orgOrder":0,"company":"Apeiron Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRIA","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Alunacedase Alpha","moa":"ACE2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Apeiron Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Apeiron Biologics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Apeiron Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Apeiron Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRIA","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Alunacedase Alpha","moa":"ACE2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Apeiron Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Apeiron Biologics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Apeiron Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Apeiron Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRIA","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Alunacedase Alpha","moa":"ACE2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Apeiron Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Apeiron Biologics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Apeiron Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Apeiron Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRIA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"RhACE2 APN01","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Apeiron Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Apeiron Biologics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Apeiron Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Apeiron Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRIA","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Alunacedase Alpha","moa":"ACE2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Apeiron Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Apeiron Biologics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Apeiron Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Apeiron Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRIA","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Alunacedase Alpha","moa":"ACE2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Apeiron Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Apeiron Biologics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Apeiron Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Apeiron Biologics","sponsor":"Neuphoria Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"BNC210","moa":"Neuronal acetylcholine receptor protein alpha-7 subunit","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Apeiron Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Apeiron Biologics \/ Apeiron Biologics","highestDevelopmentStatusID":"8","companyTruncated":"Apeiron Biologics \/ Apeiron Biologics"},{"orgOrder":0,"company":"Apeiron Biologics","sponsor":"MaxCyte","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Licensing Agreement","leadProduct":"APN401","moa":"CBLB messenger RNA (CBLB mRNA)","graph1":"Oncology","graph2":"Phase I","graph3":"Apeiron Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Apeiron Biologics \/ Apeiron Biologics","highestDevelopmentStatusID":"6","companyTruncated":"Apeiron Biologics \/ Apeiron Biologics"},{"orgOrder":0,"company":"Apeiron Biologics","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Antibody","year":"2024","type":"Acquisition","leadProduct":"Dinutuximab","moa":"Disialoganglioside GD2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Apeiron Biologics","amount2":0.13,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.13,"dosageForm":"Infusion","sponsorNew":"Apeiron Biologics \/ Ligand Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Apeiron Biologics \/ Ligand Pharmaceuticals"},{"orgOrder":0,"company":"Apeiron Biologics","sponsor":"Apeiron Respiratory Therapies GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRIA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Apeiron Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Apeiron Biologics \/ Apeiron Respiratory Therapies GmbH","highestDevelopmentStatusID":"6","companyTruncated":"Apeiron Biologics \/ Apeiron Respiratory Therapies GmbH"},{"orgOrder":0,"company":"Apeiron Biologics","sponsor":"Domainex","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"APN431","moa":"E3 ubiquitin ligase CBL-B","graph1":"Oncology","graph2":"Discovery","graph3":"Apeiron Biologics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Apeiron Biologics \/ Apeiron Biologics","highestDevelopmentStatusID":"2","companyTruncated":"Apeiron Biologics \/ Apeiron Biologics"}]

    Find Clinical Drug Pipeline Developments & Deals by Apeiron Biologics

    Menu

    Apeiron Biologics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Apeiron Biologics

                            Austria arrow
                            SCI Medicinal Chemistry
                            Not Confirmed

                            Apeiron Biologics

                            Austria arrow
                            SCI Medicinal Chemistry
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dinutuximab

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Ligand Pharmaceuticals

                            Deal Size : $128.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Ligand to Acquire APEIRON Biologics AG for $100 Million

                            Details : Ligand acquires Apeiron Biologics pipeline which also includes Qarziba (dinutuximab beta), it is indicated for the treatment of high-risk neuroblastoma in patients aged 12 months and above.

                            Product Name : Qarziba

                            Product Type : Antibody

                            Upfront Cash : $100.0 million

                            August 07, 2024

                            Lead Product(s) : Dinutuximab

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Ligand Pharmaceuticals

                            Deal Size : $128.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Apeiron Biologics

                            Austria arrow
                            SCI Medicinal Chemistry
                            Not Confirmed

                            Apeiron Biologics

                            Austria arrow
                            SCI Medicinal Chemistry
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Alunacedase Alpha

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            APEIRON Respiratory Therapies Announces Positive Results From Phase I Trial of Inhaled APN01

                            Details : The study met all primary and secondary endpoints, with all results indicating that the inhalation of APN01 (alunacedase alfa) at all dosage levels used in the trial is safe and well tolerated.

                            Product Name : Undisclosed

                            Product Type : Enzyme

                            Upfront Cash : Inapplicable

                            February 11, 2022

                            Lead Product(s) : Alunacedase Alpha

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Apeiron Biologics

                            Austria arrow
                            SCI Medicinal Chemistry
                            Not Confirmed

                            Apeiron Biologics

                            Austria arrow
                            SCI Medicinal Chemistry
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Alunacedase Alpha

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Apeiron Biologics Begins Phase 1 Trial to Treat Covid-19 with Inhaled APN01

                            Details : Primary study objective is the evaluation of safety and tolerability of single ascending doses (SADs) and multiple ascending doses (MADs) of inhaled APN01 when administered via a jet nebulizer in healthy subjects.

                            Product Name : Undisclosed

                            Product Type : Enzyme

                            Upfront Cash : Inapplicable

                            December 10, 2021

                            Lead Product(s) : Alunacedase Alpha

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Apeiron Biologics

                            Austria arrow
                            SCI Medicinal Chemistry
                            Not Confirmed

                            Apeiron Biologics

                            Austria arrow
                            SCI Medicinal Chemistry
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SNS-301,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Recipient : Sensei Biotherapeutics

                            Deal Size : $30.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Sensei Biotherapeutics Announces $30 Million Financing to Advance Proprietary ImmunoPhage™ Platform and Onco...

                            Details : Sensei’s lead ImmunoPhage product candidate, SNS301, is being evaluated in a Phase 1/2 trial for the treatment of locally advanced unresectable or metastatic squamous cell carcinoma of the head and neck (SCCHN) in combination with pembrolizumab.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            November 01, 2021

                            Lead Product(s) : SNS-301,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Sensei Biotherapeutics

                            Deal Size : $30.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Apeiron Biologics

                            Austria arrow
                            SCI Medicinal Chemistry
                            Not Confirmed

                            Apeiron Biologics

                            Austria arrow
                            SCI Medicinal Chemistry
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Apeiron Respiratory Therapies GmbH

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Inhaled APN01 Developed as ...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            October 04, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Apeiron Respiratory Therapies GmbH

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Apeiron Biologics

                            Austria arrow
                            SCI Medicinal Chemistry
                            Not Confirmed

                            Apeiron Biologics

                            Austria arrow
                            SCI Medicinal Chemistry
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BNC210

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Recipient : Neuphoria Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            $16 Million Capital Raise to Progress Bionomics BNC210 PTSD Trial

                            Details : Under the Subscription Agreement dated 2 June 2020 with Apeiron, Apeiron agreed to recapitalise the Company and assist in securing further equity capital to fund the Company's BNC210 Phase 2b Clinical trial for the treatment of post-traumatic stress diso...

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            October 02, 2021

                            Lead Product(s) : BNC210

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Recipient : Neuphoria Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Apeiron Biologics

                            Austria arrow
                            SCI Medicinal Chemistry
                            Not Confirmed

                            Apeiron Biologics

                            Austria arrow
                            SCI Medicinal Chemistry
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Alunacedase Alpha

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Lancet Publishes Promising Data of Apeiron's APN01 (rhsACE2) to Treat COVID-19 in Named Patient Use

                            Details : Case study from promising first COVID-19 patient treatment with APN01 supports APEIRON’s ongoing pivotal Phase II clinical trial.

                            Product Name : Undisclosed

                            Product Type : Enzyme

                            Upfront Cash : Inapplicable

                            September 25, 2020

                            Lead Product(s) : Alunacedase Alpha

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Apeiron Biologics

                            Austria arrow
                            SCI Medicinal Chemistry
                            Not Confirmed

                            Apeiron Biologics

                            Austria arrow
                            SCI Medicinal Chemistry
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : APN431

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Recipient : Domainex

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Expansion of APEIRON Biologics and Domainex Partnership will Advance Cancer Drug Discovery

                            Details : Domainex will provide its expertise in medicinal and computational chemistry, screening, structural biology and ADME/PK to advance APEIRON’s promising Cbl-b targeting compound series APN431 towards pre-clinical development.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            September 11, 2020

                            Lead Product(s) : APN431

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Recipient : Domainex

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Apeiron Biologics

                            Austria arrow
                            SCI Medicinal Chemistry
                            Not Confirmed

                            Apeiron Biologics

                            Austria arrow
                            SCI Medicinal Chemistry
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : APN401

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : MaxCyte

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            APEIRON Biologics and MaxCyte Enter Into Clinical and Commercial Licensing Agreement for APN401

                            Details : Under the terms of this licensing agreement, APEIRON to utilize MaxCyte's ExPERT® platform for siRNA-based cell therapy APN401 targeting solid tumors and secures manufacturing for upcoming clinical trials.

                            Product Name : Undisclosed

                            Product Type : Oligonucleotide

                            Upfront Cash : Undisclosed

                            July 07, 2020

                            Lead Product(s) : APN401

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : MaxCyte

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Apeiron Biologics

                            Austria arrow
                            SCI Medicinal Chemistry
                            Not Confirmed

                            Apeiron Biologics

                            Austria arrow
                            SCI Medicinal Chemistry
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RhACE2 APN01

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            April 06, 2020

                            Lead Product(s) : RhACE2 APN01

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth